14Apr
13Apr
Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). Read more >>
13Apr
Akston Biosciences CEO to Present at the World Vaccine Congress
Akston Biosciences Corporation, a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this year’s World Vaccine Congress (WVC). This is the largest, most prestigious meeting dedicated to vaccines and will be held on April 18-21 in Washington, DC. In addition, the company’s Fc-fusion protein platform has been shortlisted in the best new vaccine technology category of the World Vaccine Congress Vaccine Industry Excellence (ViE) Awards. Read more...
08Apr
Wasabi Technologies Partners with the Boston Red Sox Through Multi-Year Sponsorship Deal with Fenway Sports Group
Wasabi Technologies, the hot cloud storage company, today announced a multi-year partnership with Fenway Sports Group that harnesses the power of sports and entertainment to take the Wasabi brand to new heights. Wasabi is designated a Proud Partner of the Boston Red Sox, generating unprecedented brand awareness, community relations initiatives, and client and employee engagement across Fenway Sports Group properties through 2026. With headquarters in the heart of Boston, Wasabi was founded in 2017 by Carbonite founders David Friend and...
08Apr
Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India. India’s Central Drugs Standard Control Organization (CDSCO) approved the double-blind, placebo-controlled trial, initiated by Ahmedabad-based Veeda Clinical Research Limited, whose data will be submitted in an application for Emergency Use Authorization (EUA). The multicenter trial will complete the enrollment of 1,500 healthy...
06Apr
Xylyx Bio collaboration reveals new insights into tumor drug resistance
Xylyx Bio develops physiologic disease models that enable researchers to gain insights into tumor biology and evaluate the efficacy of drug candidates. Their IN SITE™ Metastasis Kit was recently featured in a publication for a study that showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Metastatic breast cancer patients respond poorly to standard of care therapies due, in part, to the failure of conventional models to recreate the complex interactions between tumor cells and...
05Apr
Here are the winners of the INVEST Pitch Perfect contest
The MedCity INVEST Pitch Perfect contest saw some compelling presentations by four groups of entrepreneurs seeking to make a difference in healthcare. They addressed myriad pain points in care coordination, care delivery, the patient experience and improving the collection and analysis of data for clinical decision support. Startups competed across four tracks. Teams of three judges evaluated startups on criteria that included completeness of overall plan, business idea, market opportunity, business model and the founder(s)’ experience. Here’s a look at...
05Apr
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has been paid. The Company received $1.0 million of the total $2.7 million license fee...
01Apr
Aparavi and Wasabi Technologies Partner to Help Organizations Extract True ROI from High Performance Data Management
APARAVI®, the trusted disruptor in unstructured data management, and Wasabi Technologies, the hot cloud storage company, today announced a partnership agreement and validated interoperability of the Aparavi Platform with Wasabi Hot Cloud Storage to deliver improved storage consolidation and management. Users will benefit from reduced risks and costs by giving them the ability to move large datasets rapidly in and out of the cloud, with the luxury of a single platform for data discovery, indexing, classification, search and lifecycle management....
01Apr